Investment to develop pain therapy
A pain drug development company spun out of The University of Queensland has received a $3.25 million investment commitment to develop its innovative pain therapy.
Spinifex Pharmaceuticals, an emerging biotechnology company specialising in the development of therapeutics for the treatment of neuropathic pain, has attracted investment from a syndicate including Symbiosis Group Limited, Melbourne-based GBS Venture Partners Limited and Uniseed.
Spinifex's core technology relates to the discovery (made by University of Queensland researchers led by Professor Maree Smith) of a novel pathway for the treatment of neuropathic pain. Professor Smith's group successfully validated this pathway using small molecules in well-defined animal models of neuropathic pain.
Nanogenerator absorbs CO2, produces electricity
The technology goes further than being carbon neutral, as it consumes CO2 as it...
Fourth global coral bleaching event confirmed
The world is currently experiencing a global coral bleaching event, according to NOAA scientists....
Two new methods for faster sepsis diagnosis
Sepsis and septic shock patients could soon experience faster diagnoses and better outcomes,...
